. 2019 Oct 8;4(2):pkz079. doi: 10.1093/jncics/pkz079

Table 2.

Logistic multivariable regression analyses of selected AHO in 479 TCS

Characteristic	AHO
	Tinnitus: yes∗		Hearing loss: yes∗		Raynaud phenomenon: yes∗		Peripheral neuropathy: yes∗
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Clinical characteristic
Treatment		P _overall = .0011		P _overall = .0016		P _overall = .0014		P _overall <.0001
Surgery only	Ref.		Ref.		Ref.		Ref.
BEPx3^†	3.00 (1.61 to 5.60)	.0005	3.52 (1.71 to 7.28)	.0007	11.85 (2.74 to 51.29)	.0009	8.93 (3.04 to 26.29)	<.0001
BEPx4	3.71 (1.77 to 7.78)	.0005	3.80 (1.63 to 8.85)	.0020	20.56 (4.49 to 94.19)	<.0001	12.82 (4.01 to 40.94)	<.0001
Other chemotherapy^‡	3.99 (1.83 to 8.72)	.0005	5.20 (2.14 to 12.63)	.0003	12.04 (2.52 to 57.62)	.0018	17.63 (5.47 to 56.83)	<.0001
Age at clinical evaluation, per 5 y	1.11 (0.99 to 1.26)	.0764	1.16 (1.02 to 1.33)	.0259	1.02 (0.87 to 1.18)	.8260	1.23 (1.07 to 1.41)	.0033
Time since chemotherapy completion, per 1 y	1.00 (0.96 to 1.04)	.9636	1.01 (0.97 to 1.06)	.4898	1.02 (0.97 to 1.06)	.5031	0.96 (0.92 to 1)	.0658
Cumulative dose of cisplatin, per 100 mg/m²^§	1.44 (1.22 to 1.69)	<.0001	1.40 (1.17 to 1.66)	.0002	^§	^§	1.75 (1.41 to 2.17)	<.0001
Health behavior
Smoking status		P_overall = .4704		P _overall = .6835		P _overall = .0402		P _overall = .5185
Never smoker	Ref		Ref		Ref		Ref
Former smoker	0.83 (0.52 to 1.31)	.4261	0.81 (0.49 to 1.33)	.4002	0.93 (0.52 to 1.67)	.8146	1.27 (0.75 to 2.12)	.3740
Current smoker	1.27 (0.65 to 2.48)	.4800	0.85 (0.40 to 1.78)	.6655	2.41 (1.16 to 5.02)	.0183	1.43 (0.68 to 2.99)	.3485
Average no. alcoholic drinks in past year	^‖	^‖	^‖	^‖	^‖	^‖		P _overall = .6080
Rarely or never	^‖	^‖	^‖	^‖	^‖	^‖	Ref
≤4/wk	^‖	^‖	^‖	^‖	^‖	^‖	1.08 (0.6, 1.94)	.7885
5/wk–1/d	^‖	^‖	^‖	^‖	^‖	^‖	1.25 (0.63, 2.48)	.5178
≥2/d	^‖	^‖	^‖	^‖	^‖	^‖	1.61 (0.78, 3.34)	.2017
AHO specific risk factor
Cumulative dose of bleomycin, per 90 000 IU^§	^‖	^‖	^‖	^‖	1.36 (1.12 to 1.65)	.0016	^‖	^‖
Noise exposure		P _overall = .0189		P _overall = .0003
None	Ref		Ref		^‖	^‖	^‖	^‖
Work-related noise only	1.69 (1.02 to 2.79)	.0426	2.30 (1.32 to 4.00)	.0033	^‖	^‖	^‖	^‖
Non-work-related noise only	2.1 (1.03 to 4.25)	.0399	3.64 (1.70 to 7.81)	.0009	^‖	^‖	^‖	^‖
Both	2.13 (1.22 to 3.72)	.0078	2.75 (1.49 to 5.06)	.0012	^‖	^‖	^‖	^‖
Hypertension	1.08 (0.57 to 2.02)	.8175	2.40 (1.23 to 4.67)	.0101	1.13 (0.53 to 2.39)	.7529	1.23 (0.62 to 2.43)	.5468
CVD	1.33 (0.57 to 3.13)	.5118	1.05 (0.41 to 2.68)	.9245	0.58 (0.18 to 1.91)	.3720	0.95 (0.36 to 2.48)	.9086
Peripheral vascular disease	^‖	^‖	^‖	^‖	0.84 (0.22 to 3.12)	.7895	8.72 (2.41 to 31.62)	.0010
Diabetes and on prescription medication	^‖	^‖	^‖	^‖	2.23 (0.47 to 10.66)	.3164	1.53 (0.37 to 6.35)	.5614

Ref. = “no.” AHO = adverse health outcome; BEP = bleomycin, etoposide, cisplatin; CI = confidence interval; CVD = cardiovascular disease; EP = etoposide, cisplatin; IU = international unit; OR = odds ratio; TCS = testicular cancer survivors; VeIP = vinblastine, ifosfamide, cisplatin; VIP = etoposide, cisplatin, ifosfamide.

^†

The standard BEP chemotherapy cycle that all of our patients received consists of bleomycin 30 000 IU days 1, 8, 15; etoposide 100 mg/m² days 1 through 5; and cisplatin 20 mg/m² days 1 through 5.

^‡

Includes 32 patients with other cisplatin-based regimens: 11 participants with VIP and one with VeIP. Each standard VIP chemotherapy cycle that our patients received consists of etoposide 75 mg/m² days 1 through 5, cisplatin 100 mg/m² days 1through 5, and ifosfamide 1200 mg/m² days 1 through 5.

^§

Reported results are calculated utilizing the statistical model that included the cumulative dose variable instead of the treatment group variable. Please refer to Supplementary Methods (available online) for details on the statistical analysis modeling used.

^‖

Variable not included in the analysis for the indicated AHO. Please refer to Supplementary Methods (available online).